Abiogen, Cancer Research UK deal

Abiogen disclosed that it has an exclusive, worldwide license to a RFB4 murine MAb targeting CD22 from Cancer Research UK's Cancer Research Technology Ltd. subsidiary. Cancer Research will receive a...